Tynan Fleur E, Elhassen Diah, Purcell Anthony W, Burrows Jacqueline M, Borg Natalie A, Miles John J, Williamson Nicholas A, Green Kate J, Tellam Judy, Kjer-Nielsen Lars, McCluskey James, Rossjohn Jamie, Burrows Scott R
The Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.
J Exp Med. 2005 Nov 7;202(9):1249-60. doi: 10.1084/jem.20050864.
Thousands of potentially antigenic peptides are encoded by an infecting pathogen; however, only a small proportion induce measurable CD8(+) T cell responses. To investigate the factors that control peptide immunogenicity, we have examined the cytotoxic T lymphocyte (CTL) response to a previously undefined epitope ((77)APQPAPENAY(86)) from the BZLF1 protein of Epstein-Barr virus (EBV). This peptide binds well to two human histocompatibility leukocyte antigen (HLA) allotypes, HLA-B3501 and HLA-B3508, which differ by a single amino acid at position 156 ((156)Leucine vs. (156)Arginine, respectively). Surprisingly, only individuals expressing HLA-B3508 show evidence of a CTL response to the (77)APQPAPENAY(86) epitope even though EBV-infected cells expressing HLA-B3501 process and present similar amounts of peptide for CTL recognition, suggesting that factors other than peptide presentation levels are influencing immunogenicity. Functional and structural analysis revealed marked conformational differences in the peptide, when bound to each HLA-B35 allotype, that are dictated by the polymorphic HLA residue 156 and that directly affected T cell receptor recognition. These data indicate that the immunogenicity of an antigenic peptide is influenced not only by how well the peptide binds to major histocompatibility complex (MHC) molecules but also by its bound conformation. It also illustrates a novel mechanism through which MHC polymorphism can further diversify the immune response to infecting pathogens.
感染病原体可编码数千种潜在的抗原肽;然而,只有一小部分能诱导可检测到的CD8(+) T细胞反应。为了研究控制肽免疫原性的因素,我们检测了细胞毒性T淋巴细胞(CTL)对来自爱泼斯坦-巴尔病毒(EBV)BZLF1蛋白的一个先前未明确的表位((77)APQPAPENAY(86))的反应。该肽与两种人类组织相容性白细胞抗原(HLA)同种异型HLA-B3501和HLA-B3508结合良好,这两种同种异型在第156位氨基酸处仅相差一个氨基酸(分别为(156)亮氨酸和(156)精氨酸)。令人惊讶的是,只有表达HLA-B3508的个体显示出对(77)APQPAPENAY(86)表位的CTL反应证据,尽管表达HLA-B3501的EBV感染细胞处理并呈递相似数量的肽以供CTL识别,这表明除了肽呈递水平之外的因素正在影响免疫原性。功能和结构分析揭示了该肽与每种HLA-B35同种异型结合时存在明显的构象差异,这些差异由多态性HLA残基156决定,并直接影响T细胞受体识别。这些数据表明,抗原肽的免疫原性不仅受肽与主要组织相容性复合体(MHC)分子结合程度的影响,还受其结合构象的影响。它还阐明了一种新机制,通过该机制MHC多态性可进一步使针对感染病原体的免疫反应多样化。